UMD professor named Maryland Chemist of the Year
BALTIMORE — A University of Maryland pharmacy professor won top honors last week for his work developing a means of measuring oxygen levels in the brain, the university said Monday.
The state chapter of the American Chemical Society named Gerald Rosen its Maryland Chemist of the Year. Rosen and colleagues are developing real-time electron paramagnetic resonance imaging, or EPRI, to measure critical oxygen levels in stroke and tumor patients and to improve drug development.
The technology is based on organic compounds called nitroxides, which Rosen has spent his career synthesizing in search of a way to use them for studying physiology in targeted parts of the body.
“Dr. Rosen’s groundbreaking work to develop real-time imaging of brain function after a stroke or other events offers medicine an unprecedented new tool for evaluating and potentially treating brain injury,” UMD school of pharmacy dean Natalie Eddington said.
Report: Banning ‘pay for delay’ settlements likely won’t happen
NEW YORK — Legislation to ban patent litigation settlements between branded and generic drug companies appears unlikely to find success, according to published reports.
The Hill, a newspaper that covers Congress, reported on Sunday that language in the Senate appropriations bill that would ban so-called “pay for delay” settlements between drug makers did not appear likely to pass. The newspaper reported that the Senate appeared likely to support a resolution supported by the House that did not contain the language.
The deals, whereby a generic drug maker that has won the right to market its version of a drug prior to the expiration of the branded drug’s patent agrees to put off launching its version in exchange for the brand company paying it — in the form of cash or, more commonly, a promise not to launch an “authorized generic,” essentially the branded drug marketed under its generic name at a lower price — have attracted controversy in recent years. Opponents, including the Federal Trade Commission, said the deals unfairly keep cheaper generic drugs off the market, while supporters, including generic and brand drug makers, said they still allow generic launch before patent expiration, and that delaying launch after patent expiration would be illegal anyway.
Axium receives ACHC accreditation
LAKE MARY, Fla. — The Accreditation Commission for Health Care has accredited specialty pharmacy provider Axium Healthcare Pharmacy, Axium said Tuesday.
Axium said the accreditation was given for its headquarters in Florida and for sites in Mississippi and Puerto Rico. The ACHC was formed by home care and community-based providers with the goal of helping companies improve business operations and patient care quality. Organizations obtain accreditation by submitting to peer review of their internal policies, processes and patient care delivery, which are compared with national standards.
“Accreditation provides our patients, physicians, payers and manufacturers assurance of Axium delivering a high-quality, patient-focused care and personalized superior service,” Axium president and CEO Mark Montgomery said.